pd-l2 and pd-l1 peptide
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2017 (NCT03381768)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1Immunity, active
CD274 immunity, active
- Programmed cell death 1 ligand 2Immunity, active
PDCD1LG2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03939234 | Phase 2 | Apr 26, 2019 | IO Biotech, University of Copenhagen |
| NCT03381768 | Phase 1 | Dec 12, 2017 | University of Copenhagen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 2 | 2 | 2 | 2017 |
| IO Biotech | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1